The ING4 Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line. This loss-of-function model disrupts the tumor suppressor gene ING4 (Inhibitor of Growth 4), providing a biologically relevant system to dissect the molecular consequences of ING4 ablation in a well-characterized non-small cell lung carcinoma (NSCLC) background. As a polyclonal pool, this product captures the diverse editing outcomes within a bulk population, avoiding clonal biases while maintaining robust knockout representation. Researchers can leverage this tool to investigate ING4-dependent signaling, epigenetic regulation, and malignant phenotypes without confounding effects of single-cell adaptation.
The host A-549 cell line originates from the lung adenocarcinoma tissue of a 58-year-old Caucasian male and is widely employed as an in vitro model for NSCLC. A-549 cells exhibit typical epithelial morphology, express wild-type p53, and harbor a KRAS G12S mutation, making them particularly suitable for studying oncogenic signaling and tumor suppressor pathways. Their established use in cancer biology, drug sensitivity assays, and metastasis research provides a standardized platform for interrogating gene function. The integration of ING4 knockout into this genetic background allows for direct comparison of parental and knockout populations, facilitating pathway analysis and drug response profiling (Giard et al., 1973).
ING4 serves as a multifaceted tumor suppressor, functioning through chromatin remodeling via association with histone acetyltransferase complexes such as HBO1 and p300/CBP. It transcriptionally regulates key pathways by interacting with p53 to enhance apoptosis, inhibiting NF-??B through physical interaction with its p65 subunit, and promoting HIF-1?? degradation under normoxic conditions. These mechanisms converge to suppress cellular proliferation, angiogenesis, and migration while promoting cell cycle arrest and apoptotic sensitivity. Notably, ING4 is positively regulated by p53 and SP1, and its expression is modulated by DNA methylation and histone modifications. Downstream effectors include activation of the p53/p21/Bax axis, reduced cyclin D1 levels, and attenuation of VEGF and MMP-9 expression.
In the A-549 cellular context, loss of ING4 accurately mimics pathological downregulation observed in aggressive NSCLC and other malignancies. The knockout model abrogates ING4-mediated growth suppression, leading to enhanced NF-??B transcriptional activity, stabilization of HIF-1??, and diminished p53-dependent apoptosis. Consequently, these cells exhibit increased proliferation rates, elevated migratory and invasive capacity, and heightened angiogenic potential. This modified phenotype makes the polyclonal ING4 knockout cells an ideal system for studying the transition from indolent to aggressive tumor behavior and for evaluating therapeutic interventions targeting the ING4-regulated signaling network, including NF-??B and HIF-1?? inhibitors.
This knockout cell product supports a broad spectrum of research applications, including mechanistic studies of tumor suppression, lung cancer cell signaling, and epigenetic regulation. Representative experimental workflows encompass western blotting and RT-qPCR for expression analysis, MTT/CCK-8 and Annexin V apoptosis assays for phenotypic assessment, transwell migration/invasion assays to quantify metastatic potential, and ChIP-qPCR for histone acetylation patterns at ING4 target promoters. Additionally, NF-??B luciferase reporter assays enable real-time monitoring of pathway activity. These polyclonal cells are particularly valuable for drug sensitivity screening against novel agents targeting NF-??B, HIF-1??, or p53 pathways. For further details, please contact Ascent Research.
